The Lymphoma Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ASH 2022 | Phase Ib trial of R-CHOP plus iberdomide or golcadomide in aggressive B-cell lymphoma
Jason Westin, MD, FACP, The University of Texas MD Anderson Cancer Center, Houston, TX, describes an ongoing Phase Ib trial-in-progress assessing two cereblon-modulating agents, iberdomide and golcadomide (CC-99282), in combination with R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone), for the treatment of previously untreated aggressive B-cell lymphoma. This interview took place at the 64th ASH Annual Meeting and Exposition congress in New Orleans, LA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Transcript
We’re presenting a Phase Ib study looking at R-CHOP in combination with two very cool drugs, cereblon modifiers called CC-220, or iberdomide, or CC-99282. So, the patients are not getting both of those drugs. Instead, half the patients are getting 99282, half of them getting iberdomide, and all patients are getting R-CHOP. These cereblon-targeting drugs are the new version of lenalidomide and they have incredible promise...
We’re presenting a Phase Ib study looking at R-CHOP in combination with two very cool drugs, cereblon modifiers called CC-220, or iberdomide, or CC-99282. So, the patients are not getting both of those drugs. Instead, half the patients are getting 99282, half of them getting iberdomide, and all patients are getting R-CHOP. These cereblon-targeting drugs are the new version of lenalidomide and they have incredible promise. In single-agent trials in the past, they’ve shown very good response rates, and in combination with R-CHOP thus far, we’re seeing some impressive results. At this ASH Trials-in-Progress poster, we’re not yet presenting any data, but the study is open and accruing very well, and we’re hoping to see future studies combining cereblon agents and R-CHOP in the frontline setting.
Read more...
Disclosures
Novartis: Consultancy, Research Funding; MorphoSys/Incyte Corporation: Consultancy, Research Funding; Bristol Myers Squibb: Consultancy, Research Funding; Kite, a Gilead Company: Consultancy, Research Funding; Calithera: Consultancy, Research Funding; Iksuda: Consultancy; ADC Therapeutics: Consultancy, Research Funding; MonteRosa: Consultancy; AstraZeneca: Consultancy, Research Funding; Genentech/Roche: Consultancy, Research Funding; Merck: Consultancy; Abbvie/GenMab: Consultancy; SeaGen: Consultancy.
